[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
February 3, 1999

Coronary Events With Lipid-Lowering Therapy: The AFCAPS/TexCAPS Trial

Author Affiliations

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim Co-EditorIndividualAuthor

JAMA. 1999;281(5):414-419. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203

To the Editor: Although AFCAPS/TexCAPS1 resulted in a 37% decrease in heart attacks and other serious manifestations of heart disease, there were 80 deaths among participants treated with lovastatin and 77 deaths among participants treated with placebo. These results are no different than those found in either the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT)2 or the Helsinki Heart Study (HHS),3 earlier primary prevention studies that also demonstrated a statistically significant decrease in a variety of cardiac end points, but no decrease in total mortality.